2. Academic Validation
  3. Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent

Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent

  • Eur J Med Chem. 2026 Mar 5:305:118567. doi: 10.1016/j.ejmech.2026.118567.
Rong Hu 1,  Xia-Tong Hu 2,  Ying-Yue Yang 2,  Ling-Feng Du 2,  Xiong-Xiong Lan 2,  Peng Luo 2,  Cai-Hua Li 2,  Luo-Ting Yu 3,  Ning-Yu Wang 4
Affiliations

Affiliations

  • 1 Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • 2 Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
  • 3 Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Electronic address: yuluot@scu.edu.cn.
  • 4 Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China. Electronic address: wangny-swjtu@swjtu.edu.cn.
PMID: 41529442 DOI: 10.1016/j.ejmech.2026.118567
Abstract

BCL6 is regarded as a promising therapeutic target for diffuse large B-cell lymphoma. However, most of the current BCL6 inhibitors and degraders have demonstrated limited antitumor efficacy when used as monotherapy. We hypothesized that developing multitarget degraders capable of simultaneously degrading multiple lymphoma-driving proteins might yield superior anti lymphoma activity. In this study, based on the BCL6 inhibitor BI3812, we designed and identified a dual-target degrader A5, which effectively degraded both BCL6 and GSPT1. A5 induced the degradation of BCL6 and GSPT1 in a time- and concentration-dependent manner, restored the expression of BCL6-regulated genes, and significantly promoted DNA damage in Farage cells. Consequently, A5 exhibited enhanced antiproliferative activity compared to the BCL6 inhibitor BI3812 and the BCL6 Degrader BI3802, along with induction of cell cycle arrest and Apoptosis. Furthermore, A5 significantly downregulated BCL6 and GSPT1 protein levels in vivo. Thus, this study provides a solid foundation for the development of novel multitarget BCL6 degraders with improved anti-lymphoma potential.

Keywords

Antiproliferative; BCL6; Diffuse large B-Cell lymphoma; GSPT1; Proteolysis targeting chimeras.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z